Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Lake Street analyst Frank Takkinen downgrades AVITA Medical (NASDAQ:RCEL) from Buy to Hold and lowers the price target from ...
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $14 price target.
Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 202...
Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resul...
AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical", or the "Company"), a leading therapeutic acute ...
